Israël - hébreu - Ministry of Health

padagis israel pharmaceuticals ltd, israel - mebeverine hydrochloride - טבליה - mebeverine hydrochloride 135 mg - mebeverine - mebeverine - irritable bowel syndrome and conditions included in this group such as: chronic irritable colon, gastro- intestinal spasm secondary to organic diseases

Israël - hébreu - Ministry of Health

padagis israel agencies ltd, israel - loperamide hydrochloride - קפליות - loperamide hydrochloride 2 mg - loperamide - loperamide - control and symptomatic relief of acute diarrhea.

Israël - hébreu - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - טבליות עם ציפוי אנטרי - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - for active rheumatoid arthritis which is not controlled by antiinflammatory drugs. ulcerative colitis, crohn's disease, pyoderma gangrenosum.

Israël - hébreu - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sulfasalazine - טבליה - sulfasalazine 500 mg - sulfasalazine - sulfasalazine - treatment of ulcerative colitis and crohn's disease.

Israël - hébreu - Ministry of Health

trima israel pharmaceutical products maabarot ltd - ox bile extract; pancreatin - דרז'ה - pancreatin 72 mg; ox bile extract 35 mg - multienzymes and acid preparations - multienzymes and acid preparations - regulation of digestive disturbances, indigestion fermentative dyspepsia, gastroenteritis, meteorism, epigastric fullness and post prandial distress.

Israël - hébreu - Ministry of Health

dexcel ltd, israel - metformin hydrochloride - קפליות - metformin hydrochloride 850 mg - metformin - metformin - treatment of non-insulin diabetes mellitus not responding to dietary modification.

Israël - hébreu - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Israël - hébreu - Ministry of Health

sanofi israel ltd - dronedarone - טבליות מצופות פילם - dronedarone 400 mg - dronedarone - dronedarone - multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (af). due to its safety profile, multaq should only be prescribed after alternative treatment options have been considered.multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure.

Israël - hébreu - Ministry of Health

dexcel ltd, israel - verapamil hydrochloride - קפליות - verapamil hydrochloride 240 mg - verapamil - verapamil - treatment of hypertension, angina pectoris

Israël - hébreu - Ministry of Health

organon pharma israel ltd., israel - losartan potassium - טבליה - losartan potassium 50 mg - losartan - losartan - hypertension: ocsaar is indicated for the treatment of heart failure (nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to ocsaar is not recommended. renal protection in type-2 diabetic patients with proteinuria: ocsaar is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease (need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy. ocsaar is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy. the benefit of ocsaar on the primary deposite endpoint was lar